The ongoing opioid epidemic in the United States has translated into a public health emergency due to the rising cases of Neonatal Abstinence Syndrome (NAS) or Neonatal Opioid Withdrawal Syndrome (NOWS). Infants born with NAS are at risk for low birth weight, respiratory and feeding difficulties, seizures, and disruption of infant-caregiver attachment, there are also persistent subacute symptoms that can last for months including poor feeding, difficulty sleeping, hypertonia, and loose stools. Historically, many of these infants received prolonged inpatient care with discharge occurring after the most troublesome symptoms had decreased in severity and there was establishment of supportive services. With a shift in focus to non-pharmacologic support, a new scoring tool, and the ability for prn only doses of medication, these infants are now being discharged to home significantly sooner. This results in an increased need for close primary care follow up to address risks of difficulty to console, failure to thrive, and an increased risk of child abuse or neglect. A strong outpatient support system is an important component in the care of these infants. Learn how to support these vulnerable and fragile families.
- Discuss the new management of infants affected by NAS/NOWS including a focus on non-pharmacologic management and a new scoring tool
- Review the effects that this change in management will have on timing of infant’s discharge after birth and the subsequent effects on outpatient follow up and support needs
- Review the wrap around care model that is becoming the focus for infants affected by NAS/NOWs including antenatal consults/education, changing inpatient management, and post discharge support and follow up
This seminar focuses on neonatology and was delivered at a virtual event titled, “Multidisciplinary Care of the Infant/Parent Dyad affected by NAS (Neonatal Abstinence Syndrome)/NOWS (Neonatal Opiod Withdrawal Syndrome),” on February 22, 2022.
Additional CHOP Resources:
The work presented in the presentations, videos, and other content on this site (“Presentations”) includes publicly available medical evidence, a consensus of medical practitioners, and/or opinions of individual practitioners that may differ from consensus opinions. These Presentations are intended only to provide general information and need to be adapted for each specific patient based on the practitioner’s professional judgment, consideration of any unique circumstances, the needs of each patient and their family, the availability of various resources at the health care institution where the patient is located, and other factors. The Presentations are not intended to constitute medical advice or treatment, nor should they be relied upon as such. The Presentations are not intended to create a doctor-patient relationship between/among The Children’s Hospital of Philadelphia, its physicians and the individual patients in question. The information contained in these Presentations are general in nature, and do not and are not intended to refer to specific patients.
CHOP, The Children’s Hospital of Philadelphia Foundation and its or their affiliates, the authors, presenters, practitioners, editors, and others associated with the creation of the Presentations (“CHOP”) are not responsible for errors or omissions in the Presentations; for any outcomes a patient might experience where a clinician reviewed one or more such Presentations in connection with providing care for that patient; and/or for any and all third party content on the site or in the Presentations. CHOP makes no warranty, expressed or implied, with respect to the currency, completeness, applicability or accuracy of the Presentations. Application of the information in or to a particular situation remains the professional responsibility of the practitioner who is directly treating the patient.
To the extent that the Presentations include information regarding drug dosing, in view of ongoing research, changes in government regulations and the constant flow of information relating to drug therapy and drug reactions, the viewer should not rely on the Presentation content, but rather is urged to check the package insert for each drug for indications, dosage, warnings and precautions.
Some drugs and medical devices presented in the Presentations have United States Food and Drug Administration (FDA) clearance for limited use in restricted research settings. It is the responsibility of the practitioner to ascertain the FDA status of each drug or device planned for use in their clinical practice.
You shall indemnify, defend and hold harmless CHOP, The Children’s Hospital of Philadelphia Foundation, and its/their current and former employees, officers, and agents, trustees, and their respective successors, heirs and assigns (“Indemnitees”) against any claims, liability, damage, loss or expenses (including attorneys’ fees and expenses of litigation) in connection with any claims, suits, actions, demands or judgments arising directly or indirectly out of your reference to or use of the Presentations.
The Presentations are protected by copyright laws and in some cases patent laws, and all rights are reserved under such laws. No part of the Presentations may be reproduced in any form by any means, or utilized in any other way, absent prior written permission from the copyright owner.
By starting this module, you agree to our Content Disclaimer and Terms of Service.